Stability of antisense oligonucleotides during incubation with a mixture of isolated lysosomal enzymes

International Journal of Pharmaceutics

Volumn 133, Issue 1-2, 1996, Pages 257-263

  Hudson, Andrew J ^a   Lee, Wayne ^a   Porter, Jayne ^a   Akhtar, Jehngir ^a   Duncan, Ruth ^b   Akhtar, Saghir ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antisense; Intracellular fate; Lysosomes; Oligonucleotide stability; Phosphorothioate; Tritosomes

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LYSOSOME ENZYME;

ANIMAL CELL; ARTICLE; DRUG DEGRADATION; DRUG STABILITY; HYDROLYSIS; LYSOSOME; NONHUMAN; PH; PRIORITY JOURNAL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 0029939489     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(95)04390-X     Document Type: Article

References (27)

1. Agrawal, S. and Akhtar, S., Advances in antisense efficacy and delivery. Trends Biotechnol., 13 (1995) 197-199.
2. Akhtar, S., Delivery Strategies for Antisense Oligonucleotide Therapeutics. CRC Press, Boca Raton, USA, 1995.
3. Akhtar, S. and Juliano, R.L., Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol., 2 (1992) 139-144.
4. Akhtar, S., Basu, S., Wickstrom, E. and Juliano, R.L., Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res., 19 (1991a) 5551-5559.
5. Akhtar, S., Kole, R. and Juliano, R.L., Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci., 49 (1991b) 1793-1801.
6. Akhtar, S., James, H. and Gibson, I., Molecular DIY with hairpins and hammerheads. Nat. Med., 1 (1995) 300-302.
7. Applied Biosystems DNA Synthesiser User Bulletin Issue No. 13, The Evaluation and Purification of Synthetic Oligonucleotides, April 1987, Applied Biosystems (Perkin Elmer), Warrington, UK, pp. 28-39.
8. Becker, C.R., Efcavitch, J.W., Heiner, C.R. and Kaiser, N.F., Use of a reverse phase column for the HPLC purification of synthetic oligonucleotides. J. Chromatogr., 326 (1985) 293-299.
9. Beltinger, C., Saragovi, H.U., Smith, R.M., LeSauter, L., Shah, L., DeDionisio, L., Christensen, L., Raibie, A., Jarett, L. and Gewirtz, A.M., Binding, uptake and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest., 95 (1995) 1814-1823.
10. Duncan, R., Drug polymer conjugates - potential for improved chemotherapy. Anti-Cancer Drugs, 3 (1992) 175-210.
11. Duncan, R., Lloyd, J.B. and Kopecek, J., Degradation of side chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal enzymes. Biochim. Biophys. Res. Commun., 94 (1980) 284-290.
12. Duncan, R., Cable, H.C., Lloyd, J.B., Rejmanova, P. and Kopecek, J., Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side chains in poly N-(2-hydroxypropyl)methacrylamide copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem., 184 (1984) 1997-2008.
13. Duncan, R. Vasey, P.A., Kaye, S.B. and Cassidy, J., Development of PK1, an HPMA copolymer doxorubicin conjugate. EORTC Early Drug Development Meeting, Corfu, June 1995.
14. Hawley, P. and Gibson, I. The detection of oligodeoxynucleotide molecules following uptake into mammalian cells. Antisense Res. Dev., 2 (1992) 119-127.
15. Krieg, A., Uptake and localization of phosphodiester and chimeric oligodeoxynucleotides in normal and leukemic primary cells. In Akhtar, S. (Ed.), Delivery Strategies for Antisense Oligonucleotide therapeutics, CRC Press, Inc., Boca Raton, USA, 1995, pp. 177-190.
16. Loke, S.L., Stein C., Zhang, X.H., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J.S. and Neckers, L.M., Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA, 86 (1989) 3474-3478.
17. Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning: A Laboratory Manual, Vol 1-3, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, pp. 11.28, E5.
18. Seymour, L.W., Ulbrich K., Styger, P.S., Brereton, M., Subr V., Strohalm, J. and Duncan, R., Tumor tropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer, 70 (1994) 636-641.
19. Shoji, Y., Akhtar, S., Periasamy, A., Herman, B. and Juliano, R.L., Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res., 19 (1991) 5543-5550.
20. Stein, C.A. and Cheng, Y.-C., Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science, 261 (1993) 1004-1012.
21. Stein, C.A., Tonkinson, J.L., Zhang, L.-M., Yakubov, L., Gervasoni, J., Taub, R. and Rotenberg, S.A., Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry, 32 (1993) 4855-4861.
22. Subr, V., Strohalm, J., Ulbrich, K. and Duncan, R., Polymers containing enzymatically degradable bonds. 12. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[n-(2-hydroxypropyl)-methacrylamide] copolymer drug carriers in vitro and antitumor-activity measured in vivo. J. Controlled Release, 18 (1992) 123-132.
23. Tonkinson, J.L. and Stein, C.A., Patterns of intracellular compartmentalization, trafficking and acidification of 5′-fluorescein phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res., 22 (1994) 4268-4275.
24. Trouet, A. Isolation of modified liver lysosomes. In Fleischer, S. and Packer, L. (Eds.), Methods in Enzymology, Vol. XXXI, Academic Press, New York, 1974, pp. 323-329.
25. Wagner, R., Gene Inhibition using antisense oligonucleotides. Nature, 372 (1994) 333-335.
26. Wu-Pong, S., Weiss, T.L. and Hunt, C.A., Antisense c-myc oligonucleotide cellular uptake and activity. Antisense Res. Dev., 4 (1994) 155-163.
27. Yakubov, L.A., Deeva, E.A, Zarytova, V.F., Ivanova, E.M., Ryte, A.S., Yurchenko, L.V. and Vlassov, V.V., Mechanism of oligonucleotide uptake by cells: involvement of receptors? Proc. Natl. Acad. Sci. USA, 86 (1989) 6454-6458.